Akeso Reported 2022 Annual Results
Patient Enrollment Completed for Phase III Clinical Trial of Akeso’s Cadonilimab in Treatment of Gastric Cancer
China NMPA Approved 安尼可® (Penpulimab) for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC
Who We Are?
A pioneer in developing innovative antibodies

Akeso, Inc. (HKEX Code: 9926. HK) is a biopharmaceutical company founded by a team of scientists with rich experience in global drug development and focuses on the unmet clinical needs worldwide in major diseases. The Company has created a unique integrated R&D innovation system with a comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system, and a commercialization system with an advanced operation mode. 

Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values so as to become a leading global biopharmaceutical enterprise.

Foreign cooperation

If you have any products or opportunities to cooperate and develop with us

图层 0 (4) logo图层 2 (1) logo图层 1 (1) logo图层 3 (1) logo图层 4 (1) logo
Product pipeline

We have One of the richest and most diversified innovative antibody drug pipeline in China

组 6 (2) logo